Current National Capacity Projections (Tests/ Month)

- March 2021: 344M
- June 2021: 716M
- September 2021: 950M
- December 2021: 1,076M

No changes this week.

What Happened Last Week

The FDA issued six new EUAs and nine amendments to existing EUAs

- New EUAs (3):
  - Molecular Tests (2): PathogenDX DetectX-Rv | Kaiser Permanente
  - Serology Tests (1): Inova Diagnostics QUANTA Flash

- New Amendments to Existing EUAs (11):
  - Molecular Tests (6): Quidel Lyra | Cepheid Xpert Omni | OPTI Medical Systems | BD MAX System | Euroimmun EURORealTime | Illumina COVIDSeq
  - Serology Tests (3): Megna Health | Access Bio CareStart | Sugentech SGTi-flex
  - AntigenTests (1): Abbott BinaxNOW
  - Flu/RSV Panels (1): NeuMoDx

Special Section: Workplace Commons Employer Survey

- Arizona State University, with support of The Rockefeller Foundation, has released the results of the Back to the Workplace: Are we there yet? Insights from Employers One Year into the Pandemic, from more than 1300 employers across 24 industry sectors in 31 countries.

- The survey examined employer sentiments on everything from testing to vaccination to employee support and mental health.
Two unexpected and surprisingly high numbers were that 68% of employers are testing at least some portion of their workforce and a whopping 88% plan to require or at least encourage vaccination.

Perhaps less surprising, work from home and the stress of living under a pandemic is taking its toll. Mental health is now a top priority of 77% of employers.

Food for Thought

*What we’re reading about the dilemmas of returning to the workplace and the role of testing.*

- Will workplace testing become the norm? Recently, the Biden administration issued guidance clarifying that federal agencies can mandate employee testing to enter workplaces as long as they provide clear information about the type and purpose of test, how the results will be managed, and any consequences for refusing to test.

- Can regular testing of workers slow the spread of COVID-19? With vaccine rollout rightly receiving most of the credit for our evolving ability to control the pandemic, serial testing programs will also likely prove to be a major contribution. A new North Carolina program is piloting regular, at-home self-administered tests. Experts advice that making tests available frequently and regularly will not only expedite a safe return to work, but control disease spread overall.

- Based on a theoretical model meant to quantify factors relevant to office workers, new research from MIT suggests that the six foot rule becomes inadequate after a critical time (depending on size and density). The model demonstrated that the risk of COVID exposure is the same at six feet as it is at sixty feet inside a room with mixed air.

- Not all workplaces are created equal: new research published in the journal Thorax has shown that people who work in shifts are more likely to be hospitalized with COVID than traditional 9-5 workers, with more irregular shift patterns associated with higher risk.

*The last two months weeks have seen tremendous positive shift in school reopening*

- According to Burbio’s latest data: Only 5.6% of K-12 kids are in virtual only schools.
  - % US K-12 students attending "virtual-only" schools = 5.6% (9.4% last week) vs. 27.5% in early March
  - % US K-12 students attending "traditional" in-person/every day" schools = 65.3% (from 62.4%)
  - % US K-12 students attending "hybrid" schools = 29.1% (from 28.2%)
# Latest Monthly Capacity Estimates

## Estimated Monthly Capacity of All Tests (M)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antigen Point of Care EUA Today</td>
<td>28</td>
<td>95</td>
<td>111</td>
<td>131</td>
<td>145</td>
<td>181</td>
<td>168</td>
<td>180</td>
<td>205</td>
<td>215</td>
<td>225</td>
<td>225</td>
<td>225</td>
<td>225</td>
</tr>
<tr>
<td>Home / Self Tests EUA Today</td>
<td>0</td>
<td>2</td>
<td>6</td>
<td>7</td>
<td>17</td>
<td>19</td>
<td>21</td>
<td>38</td>
<td>45</td>
<td>55</td>
<td>63</td>
<td>75</td>
<td>77</td>
<td>80</td>
</tr>
<tr>
<td>Molecular Point of Care EUA Today</td>
<td>4</td>
<td>5</td>
<td>8</td>
<td>10</td>
<td>12</td>
<td>12</td>
<td>12</td>
<td>13</td>
<td>20</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td><strong>Subtotal POC &amp; Home EUA Today</strong></td>
<td>32</td>
<td>103</td>
<td>125</td>
<td>147</td>
<td>174</td>
<td>192</td>
<td>202</td>
<td>231</td>
<td>270</td>
<td>290</td>
<td>308</td>
<td>321</td>
<td>324</td>
<td>327</td>
</tr>
<tr>
<td>Antigen Point of Care Future</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25</td>
<td>87</td>
<td>130</td>
<td>165</td>
<td>185</td>
<td>200</td>
<td>225</td>
<td>245</td>
<td>255</td>
<td></td>
</tr>
<tr>
<td>Home / Self Tests Future</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>86.4</td>
<td>118</td>
<td>144</td>
<td>160</td>
<td>170</td>
<td>186</td>
<td>186</td>
<td>192</td>
<td></td>
</tr>
<tr>
<td>Molecular Point of Care Future</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>10</td>
<td>10</td>
<td>12</td>
<td>12</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal POC &amp; Home Future</strong></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>83</td>
<td>183</td>
<td>258</td>
<td>321</td>
<td>357</td>
<td>384</td>
<td>425</td>
<td>445</td>
<td>461</td>
<td></td>
</tr>
<tr>
<td>Total POC &amp; Home</td>
<td>32</td>
<td>103</td>
<td>125</td>
<td>147</td>
<td>174</td>
<td>275</td>
<td>385</td>
<td>489</td>
<td>592</td>
<td>647</td>
<td>692</td>
<td>746</td>
<td>789</td>
<td>788</td>
</tr>
<tr>
<td>Antigen Central Lab Today</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>7</td>
<td>7</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Antigen Central Lab Future</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>28</td>
<td>30</td>
<td>32</td>
<td>37</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Lab-Based PCR Today</td>
<td>75</td>
<td>100</td>
<td>100</td>
<td>105</td>
<td>115</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>120</td>
<td>125</td>
<td>125</td>
<td>130</td>
<td>130</td>
</tr>
<tr>
<td>Add’l Lab Based PCR with Pooling</td>
<td>0</td>
<td>0</td>
<td>25</td>
<td>38</td>
<td>48</td>
<td>59</td>
<td>59</td>
<td>67</td>
<td>77</td>
<td>77</td>
<td>80</td>
<td>80</td>
<td>105</td>
<td>105</td>
</tr>
<tr>
<td><strong>Total Central Lab</strong></td>
<td>75</td>
<td>100</td>
<td>128</td>
<td>150</td>
<td>170</td>
<td>215</td>
<td>217</td>
<td>227</td>
<td>237</td>
<td>242</td>
<td>258</td>
<td>258</td>
<td>288</td>
<td>288</td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td>107</td>
<td>203</td>
<td>253</td>
<td>297</td>
<td>344</td>
<td>490</td>
<td>602</td>
<td>716</td>
<td>828</td>
<td>889</td>
<td>950</td>
<td>1004</td>
<td>1057</td>
<td>1076</td>
</tr>
</tbody>
</table>

## Estimated Future Capacity, by Test Type

- **Central Lab PCR EUAs (Today)**
- **Central Lab Antigen + Pooling (Future)**
- **POC + Home EUAs (Today)**
- **POC + Home (Future)**

### Editor
Mara G. Aspinall, MBA, Arizona State University

### Contributors
- Melea Atkins, MBA, COVID-19 Response Advisors
- Simon Johnson, PhD, Massachusetts Institute of Technology
- Brandon M. Henry, MD, Cincinnati Children's Hospital Medical Center
- Andrea Ciaranello, MD, MPH Massachusetts General Hospital
- Sarah Igoe, MD, MBA, Arizona State University

### Designer
Fer Sagastume, COVID-19 Response Advisors

*Based on published reports, company interviews, and proprietary analysis*

A collaboration between COVID-19 Response Advisors & Health Catalysts Group

[www.covidresponseadvisors.org](http://www.covidresponseadvisors.org) & [www.healthcatalysts.com](http://www.healthcatalysts.com)